{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:52:22Z","timestamp":1792065142117,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":264,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NAM Journal"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.namjnl.2026.100136","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:24:51Z","timestamp":1790148291000},"page":"100136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Six decades of evidence: biological factors predominate among reported reasons for clinical drug failure"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-9765","authenticated-orcid":false,"given":"Dilyana","family":"Filipova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5061-2377","authenticated-orcid":false,"given":"Kathrin","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-6199","authenticated-orcid":false,"given":"Andrew","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Lickiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-0421","authenticated-orcid":false,"given":"Christian","family":"Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaby","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5315-284X","authenticated-orcid":false,"given":"Merel","family":"Ritskes-Hoitinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Zietek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.namjnl.2026.100136_bib0018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41416-020-01033-x","article-title":"Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials","volume":"123","author":"Atkins","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.namjnl.2026.100136_bib0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.yrtph.2018.04.018","article-title":"A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans","volume":"96","author":"Clark","year":"2018","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"6","key":"10.1016\/j.namjnl.2026.100136_bib0027","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.namjnl.2026.100136_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.namjnl.2026.100119","article-title":"Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure","volume":"2","author":"Filipova","year":"2026","journal-title":"NAM Journal"},{"key":"10.1016\/j.namjnl.2026.100136_bib0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"2","key":"10.1016\/j.namjnl.2026.100136_bib0003","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/acs.chemrestox.0c00311","article-title":"New associations between drug-induced adverse events in animal models and humans revealnovel candidate safety targets","volume":"34","author":"Giblin","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.namjnl.2026.100136_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12910-015-0043-7","article-title":"Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research","volume":"16","author":"Green","year":"2015","journal-title":"BMC Med Ethics"},{"issue":"12","key":"10.1016\/j.namjnl.2026.100136_bib0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrd.2016.184","article-title":"Phase II and phase III failures: 2013\u20132015","volume":"15","author":"Harrison","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.namjnl.2026.100136_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2024.1355044","article-title":"The (misleading) role of animal models in drug development","volume":"4","author":"Hartung","year":"2024","journal-title":"Front Drug Discov"},{"issue":"12","key":"10.1016\/j.namjnl.2026.100136_bib0004","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of investigational drugs in late-stage clinical development and publication of trial results","volume":"176","author":"Hwang","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.namjnl.2026.100136_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002667","article-title":"Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications","volume":"22","author":"Ineichen","year":"2024","journal-title":"PLOS Biology"},{"issue":"4","key":"10.1016\/j.namjnl.2026.100136_bib0028","first-page":"320","article-title":"Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility","volume":"24","author":"Knight","year":"2007","journal-title":"ALTEX - Alternatives to Animal Experimentation"},{"issue":"8","key":"10.1016\/j.namjnl.2026.100136_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10.1016\/j.namjnl.2026.100136_bib0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12967-019-1976-2","article-title":"Animal to human translation: a systematic scoping review of reported concordance rates","volume":"17","author":"Leenaars","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.namjnl.2026.100136_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2026.1731947","article-title":"A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics","volume":"8","author":"Liu","year":"2026","journal-title":"Front Toxicol"},{"key":"10.1016\/j.namjnl.2026.100136_bib0008","first-page":"1","article-title":"Human disease models in drug development","author":"Loewa","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"10.1016\/j.namjnl.2026.100136_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/02611929231157756","article-title":"Poor translatability of biomedical research using animals \u2014 A narrative review","author":"Marshall","year":"2023","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.namjnl.2026.100136_bib0016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to first-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"3","key":"10.1016\/j.namjnl.2026.100136_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.namjnl.2026.100136_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"3","key":"10.1016\/j.namjnl.2026.100136_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"7586","key":"10.1016\/j.namjnl.2026.100136_bib0021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmj.39048.407928.BE","article-title":"Comparison of treatment effects between animal experiments and clinical trials: systematic review","volume":"334","author":"Perel","year":"2007","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.namjnl.2026.100136_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/ani10071194","article-title":"Alzheimer\u2019s Disease, and breast and prostate Cancer research: translational failures and the importance to monitor outputs and impact of funded research","volume":"10","author":"Pistollato","year":"2020","journal-title":"Animals"},{"issue":"3","key":"10.1016\/j.namjnl.2026.100136_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.namjnl.2026.100136_bib0013","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.namjnl.2026.100136_bib0010","doi-asserted-by":"crossref","unstructured":"Sewell F, Jones D, Roberts R. Regulatory momentum for new approach methodologies (NAMs) in medicines development: from vision to implementation. Current Opinion in toxicology. 2026;100609. doi:10.1016\/j.cotox.2026.100609.","DOI":"10.1016\/j.cotox.2026.100609"},{"issue":"2","key":"10.1016\/j.namjnl.2026.100136_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104608","article-title":"Organoids in drug development: from predictive models to regulatory integration","volume":"31","author":"Song","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.namjnl.2026.100136_bib0017","doi-asserted-by":"crossref","unstructured":"van Meer PJK, Kooijman M, Gispen-de Wied CC, Moors EHM, Schellekens H. The ability of animal studies to detect serious postketing adverse events is limited. Regulatory toxicology and pharmacology. 2012;64(3):345\u20139. doi:10.1016\/j.yrtph.2012.09.002.","DOI":"10.1016\/j.yrtph.2012.09.002"},{"issue":"3","key":"10.1016\/j.namjnl.2026.100136_bib0029","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/026119291003800309","article-title":"Validating animal models for preclinical research: A scientific and ethical discussion","volume":"38","author":"Varga","year":"2010","journal-title":"Altern Lab Anim"},{"issue":"6796","key":"10.1016\/j.namjnl.2026.100136_bib0009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.aeb0045","article-title":"Reimagining human-centric drug development with new approach methodologies","volume":"392","author":"Wu","year":"2026","journal-title":"Science"}],"container-title":["NAM Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050620426000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050620426000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:06:45Z","timestamp":1792062405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050620426000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":30,"alternative-id":["S3050620426000618"],"URL":"https:\/\/doi.org\/10.1016\/j.namjnl.2026.100136","relation":{},"ISSN":["3050-6204"],"issn-type":[{"value":"3050-6204","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Six decades of evidence: biological factors predominate among reported reasons for clinical drug failure","name":"articletitle","label":"Article Title"},{"value":"NAM Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.namjnl.2026.100136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100136"}}